Clinical trial
An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder
NCT05439616 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder
- Lead sponsor
- AbbVie
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 7, 2022
- Completion date
- October 4, 2024
- Enrollment
- 161 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.